Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03368859 · ClinicalTrials.gov registry record · Phase 2
A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
A Phase 2 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT03368859 is a Phase 2 study that was terminated before completion, run by AbbVie. The registered enrollment target is 70 participants.
The verdict
NCT03368859, a Phase 2 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
A study to evaluate the efficacy and tolerability of ABT-165 plus FOLFIRI compared to bevacizumab plus FOLFIRI in participants with previously treated metastatic adenocarcinoma of the colon or rectum.
Interventions
- DRUG Bevacizumab
- DRUG Leucovorin
- DRUG ABT-165
- DRUG Fluorouracil - bolus
- DRUG Fluorouracil - infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2018-03-20 |
| Est. Completion | 2019-12-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03368859
The ClinicalTrials.gov registry entry for NCT03368859 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT03368859 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03368859 about?
NCT03368859 is a clinical study titled "A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab". A study to evaluate the efficacy and tolerability of ABT-165 plus FOLFIRI compared to bevacizumab plus FOLFIRI in participants with previously treated metastatic adenocarcinoma of the colon or rectum.
What is the current status of trial NCT03368859?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2018-03-20. Estimated completion is 2019-12-18.
What interventions are being tested in trial NCT03368859?
The interventions under investigation include: Bevacizumab (DRUG), Leucovorin (DRUG), ABT-165 (DRUG), Fluorouracil - bolus (DRUG), Fluorouracil - infusion (DRUG).
Who is sponsoring clinical trial NCT03368859?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.